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Comorbid diabetes and depression are a major clinical challenge as the outcomes of 
each condition are worsened by the other. This article is based on the presentations 
and discussions during an international meeting on diabetes and depression 
convened by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) in collaboration with the National Institute of Mental Health and the 
Dialogue on Diabetes and Depression. While the psychological burden of diabetes 
may contribute to depression in some cases, this explanation does not sufficiently 
explain the relationship between these two conditions. Shared biological and 
behavioral mechanisms, such as hypothalamic-pituitary-adrenal axis activation, 
inflammation, autonomic dysfunction, sleep disturbance, inactive lifestyle, poor 
dietary habits, and environmental and cultural risk factors, are important to consider 
in understanding the link between depression and diabetes. Both individual 
psychological and pharmacological depression treatments are effective in people 
with diabetes, but the current range of treatment options is limited and has shown 
mixed effects on glycemic outcomes. More research is needed to understand what 
factors contribute to individual differences in vulnerability, treatment response, and 
resilience to depression and metabolic disorders across the life course and how best 
to provide care for people with comorbid diabetes and depression in different health 
care settings. Training programs are needed to create a cross-disciplinary workforce 
that can work in different models of care for comorbid conditions. 
Co morbid diabetes and depression represent a major clinical challenge as the outcomes 
of each condition are worsened by the presence of the other (1). In October 2012, the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the Na-
tional Institutes of Health (NIH), in collaboration with the National Institute of Mental 
Health and the Dialogue on Diabetes and Depression (2), convened a meeting of experts 
from 15 countries for two primary purposes. First, there was an opportunity to present 
and summarize the current state of the science on the association between depression 
and diabetes in the areas of basic, clinical, behavioral, and public health research. The 
second aim was to identify and highlight gaps in current scientific knowledge to inform 
the direction of future research and training (3). 
This article is not a review article but rather summarizes the evidence-based pre-
sentations and discussions during the meeting and synthesizes the scientific content 
and future research recommendations. Although no conference could include 
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everyone who conducts research relevant 
to diabetes and depression at the global 
level, this conference was unique in its 
design in presenting research on findings 
related to diabetes and depression span-
ning bench science to population science. 
This article describes the major themes 
drawn from the diversity of these presen-
tations and perspectives. The structure of 
the article follows the format of the con-
ference presentations, which were di-
vided into three main areas: 1) the 
mechanisms and pathogenesis underly-
ing the depression-diabetes association, 
2) treatment of diabetes and depression, 
and 3) prevention and public health con-
sideration of the two disorders. At the 
end of each section, we have described 
the critical gaps and key opportunities to 
improve our understanding of the preva-
lence, impact, mechanism, treatment, 
and public health considerations of the 
depression -diabetes association. Greater 
detail of these research recommendations 
can be found in Tables 1-3. 
The authors were elected by the larger 
conference planning committee immedi-
ately following the conference to report 
on the presentations and recommenda-
tions of the speakers. All speakers were 
given the opportunity to review and com-
ment on the report before approving its 
final content. 
METHODOLOGICAL 
CONSIDERATIONS IN DEFINING 
DEPRESSION 
Investigations of the psychosocial corre-
lates and diabetes and depression treat-
ment trials form the foundation of our 
existing knowledge base for the preva-
lence and impact of these comorbid con-
ditions. Although the core symptoms of 
depression are essentially the same across 
cultures, the presentation may vary be-
cause of patients' and their immediate 
reference group's perception of whether 
they are depressed; this perception will 
affect help-seeking behavior and the attri-
bution of causation and issues such as 
stigma may differ across cultures (4). 
Furthermore, the term "depression" 
covers a range of problems that span mi-
nor, occasional negative mood states to 
incapacitating and treatment-resistant 
disorders. The definition of "depression" 
varies markedly across studies ranging 
from high levels of self-reported depres-
sive symptoms to diabetes-related dis-
tress to formal psychiatric diagnoses, 
such as major depressive disorder, dys-
thymi a, or adjustment disorder with 
depressed mood. Variability of measure-
ment and use of terminology have 
contributed to heterogeneity and incon-
sistency in the reported results of preva-
lence and treatment outcomes. In this 
report, we have specified the definition 
of depression where indicated by speak-
ers (e.g., depressive symptoms, diag-
nosed depression, diabetes-related 
distress). Where the definition of depres-
sion was heterogeneous or unspecified, 
we use the italicized term depression to 
denote a range of assessment techniques 
or definitions used during the presenta-
tions of the relevant literature. 
PREVALENCE AND INCIDENCE OF 
DIABETES AND DEPRESSION 
The prevalence of comorbid depression 
varies considerably by method of de-
pression assessment. For example, prev-
alence rates for elevated depressive 
symptoms range from 12-27% across 
studies of people with type 1 and type 
2 diabetes, while rates of depressive dis-
orders, as assessed by psychiatric inter-
view protocols, range from 8-15% in 
adults with type 1 and type 2 diabetes 
(5,6). There are few studies of the prev-
alence of depressive disorders in pediat-
ric populations, but these suggest that 
the rates of depression, anxiety, and dis-
tress are also elevated in children and 
young adults with type 1 diabetes com-
pared with the general population with 
prevalence rates ranging from 10-26% 
(7). Similar rates of depression are also 
seen in adolescents with type 2 diabetes 
or in populations with both type 1 and 
type 2 diabetes (8.6-14.8%) (8). Rates of 
diabetes-related distress have been 
shown to be higher (54%) than rates of 
psychiatrically diagnosed depression (9). 
Impact of Comorbid Depression and 
Diabetes 
In adults, there is only a weak relationship 
between depression and glycemic control 
(10). By contrast, there is a stronger asso-
ciation between comorbid depressive 
symptoms and a range of diabetes com-
plications (11), although this was not ob-
served in the recent Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) 
trial (12). Increased health care costs (13), 
worsened functional disability (14), and 
early mortality are seen in adults with 
comorbid diabetes and depression 
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compared with either condition alone 
(15). Higher mortality among those with 
diabetes and depression is attributable 
to a variety of medical causes rather 
than primarily cardiovascular disease as 
previously assumed (15,16) and is not 
wholly explained by traditional risk fac-
tors (17). In children and adolescents, de-
pressive symptoms are associated with 
poorer glycemic control (7) and predict 
rehospitalization and retinopathy in chil-
dren with type 1 diabetes (18,19). 
Research Recommendations: 
Phenomenology 
Much greater clarity and specificity are 
needed to describe and measure depres-
sive symptoms, diabetes-related distress, 
and specific disorders in the depressive 
spectrum. Prospective longitudinal stud-
ies of depression spectrum (e.g., major 
depressive disorder, dysthymia, etc.) 
and other psychiatric diagnoses, such as 
bipolar disorders or psychotic disorders, 
are needed in separate populations of 
people with type 1 and type 2 diabetes 
to characterize inception predictors as 
well as the course of comorbidity. There 
is a particular need for studies in children 
and adolescents with diabetes where 
there is a paucity of knowledge. More de-
tailed description and study of diabetes 
subtypes, including gestational diabetes 
mellitus and impaired glucose metabo-
lism, and phenotypes (e.g., age, ethnicity, 
BMI, diabetes duration, comorbidities, 
treatment) are needed to clarify the on-
set and comorbidity of depression and 
diabetes. 
MECHANISMS AND PATHOGENESIS 
UNDERLYING THE ASSOCIATION 
BETWEEN DIABETES AND 
DEPRESSION 
Previous epidemiological studies have 
demonstrated a bidirectional association 
between depression and diabetes (20,21), 
with most prior work focusing on under-
standing potential mechanisms by which 
diabetes leads to depression and vice 
versa. The presentations at the meeting, 
however, suggested a novel paradigm 
shift by considering shared biological 
and behavioral pathways that may simul-
taneously predispose to both affective 
and metabolic disorders. Focusing more 
on mechanisms common to the develop-
ment of both depression and diabetes 
rather than focusing on the direction of 
association may yield novel insights for 
developing improved approaches to 
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Table 1--Mechanisms and pathogenesis: future research needs and reC:qmmendations 
Mechanism 
Environmental 
factors 
HPA axis 
Inflammation 
Circadian rhythm/ 
sleep disturbance 
Behavioral factors 
Treatment factors 
Basic science 
Develop models ()f stress/depression 
in existing diabetic animal models 
to evaluate geneti<; and epigenetic 
factors, developmental stressors, 
and environmental stressors 
Design animal studies to elucidate 
the role ()f the HPA axis in 
nellroplasticity, which has 
implications for development 
of both depression and cognitive 
dysfunction in the setting of diabetes 
Conductpreclinical stlldies ofdiabetes 
and cognition/neurogenesLs that 
incorporate measures of inflammation 
(e,g,, acute phase proteins, interleukill,6, 
inflammatory signaling pathways 
including nuclearfactorcKB and p38 
mitogen-activated protein kinase, 
kynurenine:tryptophan ratio, microglia 
activation) and tests of depression-like 
behavior 
Conductstudies to understand neural 
circuitry associated with behavioral 
regulation in diabetes 
Evaluate existing antidepressantand 
antipsychotic medications in animal 
models of diabetes to determine 
mechanisms of action for treatment 
Evaluate antihyperglycemic therapies 
(e,g,, GLP agonists) as novel 
experimental treatment for diabetes 
and depression (via regulation of 
glycemiccontrol[direct mechanism) 
and/or regulation of neuroplastidty 
[indirect mechanism]) 
Clinical, behavioral, and population science 
Develop longitudinal studies to determine if neighborhood factors 
modify the association between depression and diabetes 
Develop lifecourse studies to exalJ)ine the impactofcumulative earlylife 
and environmental·stressors on incident depression and diabetes 
Incorporate static and dynamic measures of HPA axis function into human 
studies to elucidate the role of the HPA axis in depression and type 1 
and type 2 diabetes 
Use uniform cortisol salJ)pling protocols and analytic strategies across 
studies to allow comparability 
Evaluate the impact ()f corticotrophin-releasing hormone and 
ll~hydroxysteroid dehydrogenase-1 antagonists and beha\/ioral 
interventions onHPAaxis function 
Conduct studies to determine ifanti'inflamniatory strategies wollld he 
beneficial for the treatment of depression in the context of diabetes 
Conduct association studies on biomarkers of inflammation and symptoms 
of depression 
Conduct studies to determine the degree to which overlapping 
development conditions~personal, cultural, ecologicaJ~explain the 
comorbidity of diabetes and depression and how central inflammatory 
processes are to this overlap 
Conduct studies to elucidate whether the· pathogenesis· of depression in 
patients with diabetes iscausally linked to obstructive sleep apnea 
(OSA) or whether the diabetic state is the driving force in the 
development of depression independent of sleep status 
Conduct studies to elucidate disruptions in endocrine axes and 
neurotransmitter pathways comrnon to depression, diabetes, and OSA 
Design studies fo define mechanislJ)s underlying improvement in 
depression that have been associated with improved glycemic control 
as well as improved OSA 
Evaluate linkage between self-care adherence, hyperglycemia, and 
onset of depression in adults with type 1 and type 2 diabetes 
Evaluate mechanisms associated with mood changes resulting from 
physical activity in adµlts with type 1 arid type 2 diabetes 
Evaluate types of physical activity and thresholds for duration and 
intensity to produce mood improvements in adults and children of 
different ages with type 1 and type 2 diabetes 
Design adequately powered randomized controlled trials of 
antidepressants that assess metabolic risk and will allow understanding 
of how psychotropic medications interact with other risk factors for 
diabetes 
Examine existing databases for reporting possible adverse rnetabolic 
consequences of antidepressanttreatlJ)ent 
Consider the potential effects of psychotropic meditation in future 
diabetes prevention trials 
Examine the impact of sociocultural factors on the acceptability 
and outcome of treatment, preferably using collaborative research 
allowing an exchange of experience and evidence among countries 
prevention and treatment. In turn, this 
may lead to treatment and preventative 
strategies to address these two major 
public health burdens simultaneously. 
Figure 1 summarizes common patho-
genic mechanisms and their interrela-
tions discussed during the conference, 
although it is acknowledged that other 
postulated pathogenic mechanisms link-
ing these two disorders may exist. 
The traditional view of co morbid diabe-
tes and depression assumed that the self-
care burden of diabetes, coupled with the 
knowledge of the diagnosis of diabetes 
and its complications, rendered the pa-
tient with feelings of helplessness and 
hopelessness that resulted in depression. 
Studies showing higher rates of depres-
sion in people with diagnosed diabetes 
compared with undiagnosed diabetes 
support this model (22). In addition, 
the increased rate of diabetes in people 
with depression has been attributed to 
obesity-promoting health behaviors, 
such as physical inactivity and poor die-
tary habits (21). Nonadherence to self-
care routines in those already diagnosed 
with diabetes and experiencing depres-
sive symptoms has also been found, 
such that a 1-point increase in depressive 
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T<1.ble 2--Clinical aspects and treatment: future research needs and recommendations 
Phenomenology and prevalence studies Seek clarity and spedficity in future studies in measurement/ 
Depression screening 
definition of depressive $ymptoms vs. depressive disorders 
(psychiatric diagnoses) vs. diabetes distress 
Conduct prospective longitudinal studies of diabetes subtypes and 
phenotypes, especially type 1 and type 2 diabetes, to study 
inception predictors and co morbidity course 
Develop cross-culturally applicable assessment instruments allowing 
the identification of depression comorbid with diabetes 
Conduct studies to assess cost~effectivel1ess in depression screening 
in the context of intervention trials 
Conduct studies of electronic medical record surveillance to identify 
peoplewith diabetes at high riskfor depression 
Treatment modalities, care delivery, and cost-effectiveness 
Psychotherapy 
Medications 
Collaborative care 
symptom score was found to be associ-
ated with a 10% increased risk of nonad-
herence to fruit and vegetable intake and 
foot care (23). This suggests the possibility 
that there may be a mutually reinforcing 
relationship between depressive symp-
toms and decreased adherence to self-
care behaviors (23,24). 
Current research also supports a con-
tribution of biological changes in diabe-
tes, such as structural, functional, and 
neurochemical changes in the brain re-
gions responsible for affect and cognition 
in both type 1 and type 2 diabetes that 
may increase the risk of depression (25). 
Specifically, animal models have shown 
that diabetes and hyperglycemia nega-
tively affect hippocampal integrity and 
neurogenesis, reducing neuroplasticity 
and contributing to mood symptoms in 
diabetes (26). In humans, hippocampal 
neurogenesis can be indirectly as-
sessed via MRI, and hippocampal atro-
phy has been observed in people with 
diabetes (26). 
Intrauterine Environment 
The earliest influence is the intrauterine 
environment and early life conditions, 
such as fetal undernutrition and stress 
and maternal stress, which can lead to 
Determine which psychotherapeutic approaches are most effective 
for which di abet es. subpopulations and in different. types of 
depressive disorders 
Expand treatment modalities beyond cognitive behavior therapyto 
include exercise and mindfulness-based stress reduction, etc. 
Community-based programs linking nonchealth care-system 
resources 
Evaluate mechanisms of depression medication treatments in 
randomized controlled trials in type 1 and type 2 diabetes 
Identify methodologies and infrastructure to deliver economically 
sustainable, integrative collaborative care adjusted to the cultural 
and economic conditions prevailing in differentcountries and 
parts of countries 
Develop technologies to extend collaborative care to patients and 
providers 
Develop payment approaches to support case management at 
national and state level 
low birth weight and a predisposition to 
adult diabetes (27). Animal studies have 
shown an adaptive slowing of fetal 
growth rate and modification of organ 
structure in response to undernutrition 
(28). The data about the relationship 
between adverse intrauterine environ-
ment and risk for depression in adulthood 
remain inconclusive, with some studies 
suggesting a positive association while 
others have null findings (29). In human 
studies, both low birth weight and fetal 
overexposure to cortisol secondary to 
maternal stress have been associated 
with hypothalamic-pituitary-adrenal 
(HPA) axis programming and elevated 
cortisol reactivity in childhood, adoles-
cence, and adulthood, predisposing the 
individual to stress-related and metabolic 
disorders (30). 
External Environment 
Several contextual factors, including 
childhood adversity (possibly mediated 
through increased adult C-reactive pro-
tein concentration [31]), neighborhood 
environment, and poverty, also influence 
the predisposition to depression and 
diabetes. 
Poorer neighborhood physical environ-
ment (e.g., physical disorder, traffic, 
noise, decreased walkability) is associated 
with worse diet, lower physical activity 
patterns, obesity, and diabetes (32-34). 
Furthermore, worse neighborhood social 
environment (e.g., lower social cohesion 
and social capital, increased violence, de-
creased residential stability) is associated 
with higher rates of depressive symptoms 
and mental health problems (35). Cross-
sectional data sets have indicated that re-
sources promoting physical activity and 
healthy diets are associated with lower 
diabetes risk (36). Adverse neighborhood 
environments have also been associated 
with dysfunctional HPA axis activity and 
disruption of its normal circadian rhythm 
(i.e., blunted profile) (37-41) as well as 
enhanced inflammation (42,43). 
Common Interrelated Biological 
Pathways 
Both diagnosed major depression and di-
abetes are associated with HPA axis dys-
function, which manifests as subclinical 
hypercortisolism, blunted diurnal cortisol 
rhythm, or hypocortisolism with impaired 
glucocorticoid sensitivity, and increased 
inflammation (44-47). Disrupted sleep 
patterns are seen in people with major 
depression (48), and poor sleep quality 
and altered circadian rhythms are 
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Table 3--Public health and prevention: future research· needs and recornmendatic:ms 
Preventing comorbid depression and diabetes Identify and implement best practice into routine health 
Preventing diabetes in depression 
Preventing depression in diabetes 
Prilll;iry prevention of depression and di;1betes 
associated with insulin resistance and 
type 2 diabetes risk (49). All these bio-
logical pathways are activated in major 
depression and are associated with in-
sulin resistance. A recent meta-analysis 
showed that depressive symptoms are 
weakly associated with insulin resis-
tance, providing a potential link to in-
cident type 2 diabetes (50). 
Pathways Related to Medications for 
Depression 
While there have been concerns that 
certain antipsychotic medications, 
particularly some of the "atypical" or 
second-generation antipsychotic medi-
cations, are associated with a two- to 
threefold increased risk of diabetes 
(51), recently, a role of antidepressants 
in the development of diabetes has also 
been postulated (52). Cohort studies 
show a small increased risk of diabetes 
in those receiving antidepressant medi-
cations. Randomized controlled trials, 
however, have emphasized that antide-
pressants vary considerably in their 
propensity for weight gain (53) and gly-
cemic effects, ranging from hyperglyce-
mic to hypoglycemic effects (52). It 
care for integrated health services for comorbid 
depression and diabetes in different types of service and 
in different countries 
Expand economic studies of depression-diabetes 
comorbidity to non-U.S. coµntries 
Incorporate non,health care-related costs intocost-
effectiveness analyses 
Develop studies to understand the effect ofdepression and 
antidepressants on diabetes preventive interventions 
Determine if prevention or treatment of depression can 
reduce type 2 diabetes incidence 
Validate diabetes risk engines in individualswith depression 
Coriductfuture depression intervention studies in 
individl!als With diabetes in primary and subspecialty care 
settings 
Evaluate effectiveness 
Target health care providers as intervention focus 
Conduct health services stll di es to determine. the optimal 
way of delivering depression interventions,indudingthe 
use of nonprofessional workers {e.g., peer support) and 
new technologies 
Use alternative research methodologies to model more 
closely the clinical care setting (ecg., practice-based 
research networks, pragmatic trials, systems science, 
longer-term observational studies) 
Develop and test in randomized trials population-based 
interventions to reduce etiological factors associated 
with comorbid diabetes and depression, within and 
remains unclear whether the weight 
gain results from poorly treated depres-
sion or a medication side effect. The pre-
cise mechanisms by which these drugs 
may lead to weight gain and altered in-
termediate metabolism are unknown, 
not least because they may affect multi-
ple neurotransmitter receptors simulta-
neously (52,53). 
Research Recommendations: Mechanisms 
The current state of science in our un-
derstanding of the biological and behav-
ioral mechanisms linking depression and 
diabetes from animal and human stud-
ies has two important gaps. First, many 
studies have been cross-sectional, re-
sulting in residual confounding and lim-
iting our understanding of temporal 
relationships. Second, longitudinal stud-
ies typically capture a snapshot in the 
prospective associations between de-
pression and diabetes when, in reality, 
these associations are influenced by ex-
posures over the lifecourse. To address 
these critical gaps, as outlined in Fig. 1, 
prospective lifecourse studies are 
needed in both animals and humans 
with detailed phenotypic characterization 
of the intrauterine environment and the 
external environment in which individu-
als are raised, with simultaneous longi-
tudinal assessment of behavioral and 
biological pathways influenced by these 
early exposures (e.g., HPA axis function, 
inflammation, sleep/circadian rhythms). 
In animal studies, the intrauterine envi-
ronment can be directly manipulated by 
impairing placental blood flow, and in 
both animal and human studies, assess-
ment of epigenetic markers and DNA 
methylation patterns can reflect the de-
gree of fetal stress (28). These studies 
should also longitudinally assess 1) met-
abolic measures reflecting insulin resis-
tance and hyperglycemia, 2) brain 
morphology to assess the influence of 
biological and metabolic factors on neu-
roplasticity implicated in affective and 
cognitive disturbances, and 3) the 
presence/onset of specific depressive dis-
orders using a standardized approach. In 
animal studies, neuroplasticity can be di-
rectly assessed in the amygdala, but this 
cannot be directly and noninvasively as-
sessed in human studies, which is an 
important area for future research. In 
animal studies, researchers can assess 
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Figure 1-Summary of shared pathogenic mechanisms in the depression-diabetes association covered at the International Conference on 
Depression and Diabetes. 
development of depressive behaviors 
(26). What will be required in human stud-
ies is to perform standardized psychiatric 
interviews in the context of lifecourse 
studies to allow depressive disorders to 
be correctly characterized. This will ulti-
mately allow us to link depression pheno-
types more specifically to the biological 
and behavioral pathways altered, while 
determining phenotypes that are more 
strongly related to diabetes onset. Finally, 
these studies will determine which de-
pression phenotypes in the setting of 
diabetes are related to poor health behav-
iors, onset of complications, and in-
creased mortality. Accomplishing 
these lofty goals will require interna-
tional collaborations to exploit resour-
ces and existing research infrastructure, 
but lifecourse studies will be critical to 
enhancing our current understanding. 
Such studies also will help us to under-
stand the cumulative effect of multiple 
environmental stimuli, how they inter-
act with intrinsic biological changes, 
and how they influence vulnerability 
or resilience to mental health and met-
abolic disorders. Ultimately, the studies 
will help to identify potential interven-
tion periods and targets. 
Future interventional studies in animal 
models and humans should examine the 
impact of experimental therapies on pro-
posed biological and behavioral pathways 
common to depression and diabetes by 
incorporating measures of biological, be-
havioral, and brain function. Therapies 
targeting the implicated pathways may 
lead to more effective prevention and 
treatment approaches for both diabetes 
and depression. 
TREATMENT OF DIABETES AND 
DEPRESSION 
Until recently, people with diabetes 
were specifically excluded from depres-
sion treatment trials in the general pop-
ulation, and consequently, there are 
relatively few studies examining antide-
pressant and psychotherapy treatment 
of depression that specifically focus on 
diabetes. 
Psychotherapy 
Psychotherapy treatment protocols for 
depression in people with diabetes have 
predominantly used cognitive behavioral 
therapy (CBT) delivered individually by 
mental health providers or trained nurse 
case managers and are effective in reduc-
ing depressive symptoms in adults. Al-
though there are mixed effects on 
glycemic control, interventions that com-
bine diabetes self-management educa-
tion reported benefits for glycemic 
control (54). 
Although a small research base exists, 
more research is needed to test alterna-
tive behavioral intervention approaches 
for treating diabetes and depression 
(e.g., electronic-based health [eHealth] 
intervention, exercise, mindfulness-
based stress reduction). For example, 
trials of eHealth and mobile technology-
based health (mHealth) interventions 
suggest that these are less effective 
than face-to-face psychotherapeutic 
treatments (55). 
There is a lack of evidence for psycho-
therapy that specifically addresses de-
pression in children with type 1 or 
type 2 diabetes. Brief behavioral inter-
ventions with families of children with 
type 1 diabetes have been found to be 
effective in improving adherence to 
self-care behaviors and glycated hemo-
globin, suggesting that this approach 
could serve as a model for the develop-
ment of a depression-specific treatment 
intervention (56). 
Antidepressants 
Antidepressant medications lead to ame-
lioration of depressive symptoms and res-
olution of major depression in people 
with either type 1 or type 2 diabetes, 
but have mixed effects on glycemic con-
trol ranging from hyperglycemic effects 
with tricyclic antidepressant medications 
to euglycemic or slightly hypoglycemic ef-
fects with selective serotonin reuptake 
inhibitors and serotonin-noradrenaline 
reuptake inhibitors (54). Fewer than 
half of the commonly prescribed medi-
cations of these types have been tested 
for their effects on glycemic control in 
people with diabetes. Trials have not 
been designed to assess differences in 
the effectiveness of these medications 
by diabetes type. 
Collaborative Care 
Multidisciplinary team approaches to the 
identification and treatment of depres-
sion within primary care settings incorpo-
rate identification of high-risk cases, 
problem-solving therapy delivered by 
care.diabetesjournals.org 
trained nurse case managers, and medi-
cations using a stepped-care approach 
(57). The Pathways study indicated posi-
tive improvements in depression out-
comes among adults with type 1 and 
type 2 diabetes but no changes in glyce-
mic control (57). The subsequent TEAM-
care approach combined behavioral and 
pharmacological treatment of depression 
with diabetes management, leading to 
positive outcomes for depression and gly-
cemic, systolic blood pressure, and LDL-
cholesterol control and reduced health 
care costs (58). 
Research Recommendations: Treatment of 
Diabetes and Depression 
Depression Screening. Depression screen-
ing is an important first step for the iden-
tification of individuals that could benefit 
from treatment. The use of locally stan-
dardized screening instruments, such as 
the Patient Health Questionnaire-9, that 
may be widely used in primary care and 
provide consistent definitions of what 
constitutes depressive symptom thresh-
olds or cases of "depression" would facil-
itate comparative studies of depressive 
disorders in different cultures within 
and across countries. However, this ap-
proach must be evaluated in concert 
with intervention trials to assess clinical 
and cost-effectiveness (59). In the context 
of U.S. health care reform, there is an 
opportunity to develop routine surveil-
lance using electronic medical records 
for the risk of major depression and 
alert providers to intervene proactively. 
Such surveillance of the quality and pat-
terns of diabetes care would allow 
large-scale evaluation of natural experi-
ments that occur in health care delivery 
systems (60). 
Treatment Modalities and Delivery. Despite 
well-understood differences in the etiol-
ogy and pathophysiology of type 1 and 
type 2 diabetes, existing treatment stud-
ies have examined mixed populations 
making generalizations about treatment 
efficacy of antidepressant medications or 
psychotherapy by diabetes type difficult 
(54). Sample sizes for subgroups of peo-
ple with type 1 diabetes within existing 
studies are too small to allow stratified 
analyses to determine similarities or dif-
ferences in treatment modalities and 
outcomes compared with adults with 
type 2 diabetes. Studies that highlight 
whether differences occur between dia-
betes types are needed. 
The most common psychotherapeutic 
approach used to treat comorbid diabe-
tes and depression is CBT. A total of 
eight randomized controlled trials have 
evaluated the efficacy of psychothera-
peutic interventions on depression in 
mixed populations of adults with type 1 
and type 2 diabetes. Similar beneficial 
effects of low to moderate effect size 
have been observed across the studies, 
indicating the value of this approach in 
the context of multiple variations in 
length and format of delivery (e.g., 
eHealth, individual face-to-face psycho-
therapy, group psychotherapy) and audi-
ence (55). Further research is needed to 
improve the efficacy of CBT and 
determine the minimum meaningful 
"dose" needed to have the greatest 
cost-benefit for people with diabetes 
and health providers. It is also important 
to identify which of the constituent 
elements of CBT are important for the 
therapeutic effect. In addition, much 
work remains to examine treatment 
strategies for adults with type 1 diabetes, 
whose unique needs and developmental 
history with diabetes have gone un-
addressed in the current depression 
treatment literature. Research is also 
needed to examine how CBT strategies 
can be adapted to the needs of specific 
subgroups with depression and dia-
betes, such as young people feeling 
stigmatized, older adults for whom 
cognitive decline plays an increasingly 
important role, or for those with com-
plications and functional loss. 
There is also a need to expand treat-
ment modalities beyond CBT to include 
additional approaches, such as exercise 
and/or community-based programs, 
that link treatment to community re-
sources beyond health care systems, 
such as in-home (61) or community-
based treatment programs (62). For 
example, there is a significant body of 
evidence from the general population 
that exercise is an effective treatment 
for depression. There is also evidence 
that exercise contributes to diabetes 
management. Yet, there are few trials 
that have evaluated this approach as po-
tentially synergistic in treating comorbid 
depression and diabetes. Attention bias 
modification could be developed to tar-
get the HPA axis, which has been impli-
cated in the increased recurrence risk 
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of depression in people with diabetes. 
Empirically validated treatment ap-
proaches that make use of support sys-
tems (e.g., ecological approach) are 
needed to treat both depressive dis-
orders as well as diabetes-related distress, 
making use of all possible mental health 
partners and allied health advocates 
whose expertise may be complimentary 
to the health care system and may be in-
corporated into multidisciplinary ap-
proaches to treatment. 
There is a need to evaluate mecha-
nisms of pharmacological treatment us-
ing adequately powered clinical trials. 
Greater understanding is needed about 
the way psychotropic medications inter-
act with other risk factors and the effects 
of antidepressants on diabetes preven-
tion, metabolic risk, and patient safety 
in discrete samples of people with differ-
ent types of diabetes. Such studies should 
permit comparisons of the impact of the 
factors listed above in people belonging 
to different sociocultural groups. 
PREVENTION AND PUBLIC HEAL TH 
CONSIDERATIONS 
The high prevalence of comorbid diabe-
tes and depression has a number of pub-
lic health ramifications, particularly at 
the present time when many health 
care systems are becoming increasingly 
fragmented and specialized. This disad-
vantages individuals with comorbid 
physical and mental illness. The U.K. 
Disability Rights Commission has high-
lighted the concept of "overshadow-
ing," where health care professionals 
focus solely on the mental disorder 
and fail to take note of physical health 
needs, despite the greater need for this 
care (63). This translates into poorer di-
abetes care as those with mental illness 
are less likely to be screened for diabe-
tes, leading to higher rates of undiagnosed 
diabetes (64). People with comorbid 
mental illness are less likely to be offered 
screening for glycated hemoglobin or 
cholesterol, statin therapy, or diabetes 
education or be examined for microvas-
cular complications, despite more clinic 
visits. By contrast, depressive and other 
mental disorders are often missed and 
inadequately treated if the focus of 
care is the medical condition (65,66). 
These types of systematic deficiencies 
within health care systems may contrib-
ute significantly to the poorer health 
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outcomes in those with comorbid diabe-
tes and depression. 
A recent systematic review has high-
lighted the increased health service utiliza-
tion and cost associated with comorbid 
diabetes and depression (13). In addition 
to direct health costs, adverse impacts on 
workforce participation and absenteeism 
were also found. A limitation of these stud-
ies is that most were undertaken in the 
U.S., with few examining the impact beyond 
1 year or outside the health care system. 
Prevention of Diabetes in People With 
Depression 
Recent studies have shown that diabetes 
can be prevented, or at least delayed, by 
either lifestyle or pharmacological inter-
ventions (67). The development of diabe-
tes risk engines now allows a reasonably 
accurate assessment of diabetes risk in 
clinical practice. This combination of better 
identification and affordable interventions 
has made diabetes prevention a realistic 
and cost-effective proposition (68). 
Neither the risk engines nor diabetes 
prevention interventions have been 
evaluated in people with depression. 
This is important because the risk of di-
abetes is increased in people with de-
pression and may involve different 
etiological factors, while a number of 
barriers may impede the successful im-
plementation of lifestyle interventions. 
In the Diabetes Prevention Program 
(OPP), a population with prediabetes at 
enrollment, those taking antidepres-
sants had a higher risk of developing 
diabetes than those not taking antide-
pressants in the placebo and lifestyle in-
tervention arms, while the risk was 
lower in people in the metformin arm 
who did not receive lifestyle interven-
tion (69,70). In the same study, elevated 
depressive symptoms did not predict 
development of diabetes (69,70). This 
study excluded those with severe de-
pression and the wide confidence inter-
vals of the findings make it unclear 
whether these findings can be extrapo-
lated to a broader population of people 
with depression. Nevertheless, it should 
not be assumed that risk identification 
and prevention will be equally effective 
in people with depression in the absence 
of scientific evidence. 
Prevention of Depression in People 
With Diabetes 
Many risk factors that predict the onset 
of depression in the general population 
are equally applicable to people with 
diabetes, but there are several diabetes-
specific factors, such as the development 
of complications (11) and the need for 
insulin treatment in people with type 2 
diabetes (71), that are associated with 
an increased prevalence of depression. 
Despite our understanding of the epide-
miology, there has been little research 
into the prevention of depression in 
people with diabetes. This is also true 
in people without diabetes, where 
most interventions have focused on sec-
ondary prevention. A recent systematic 
review concluded that there was inade-
quate evidence to determine the clinical 
effectiveness or cost-effectiveness of 
low-intensity psychological interven-
tions to prevent relapse or recurrence 
of depression (72). 
The large numbers of people with dia-
betes at risk for depression demand effica-
cious and cost-effective interventions. This 
may involve the use of nonprofessional 
workers (e.g., peers) or new technologies 
to deliver the preventative interventions. 
Primary Prevention of Depression and 
Diabetes 
There are many shared risk factors for di-
abetes and depression, suggesting that 
diabetes and depression may be two 
manifestations of a common set of psy-
chological, lifestyle, and biological pertur-
bations. It is therefore possible that 
population approaches that focus on the 
common ground between diabetes and 
depression and the behaviors that relate 
to both may allow the effective preven-
tion of both conditions, but this area is 
largely not researched. 
Research Recommendations: Prevention 
and Public Health Considerations 
Prevention. It is unclear whether effective 
prevention or treatment of depression 
can reduce incidence of type 2 diabetes. 
Future trials are needed to address this 
issue while validation of diabetes risk en-
gines in people with depression is needed 
to identify those at high risk of diabetes. 
The interaction of depression and antide-
pressants on interventions to prevent di-
abetes also merits further study. 
Future research should examine when 
and how interventions to prevent depres-
sion can be introduced in people with 
diabetes. Such research should be con-
ducted in people with diabetes in both 
primary and specialty care settings to 
evaluate the effectiveness of interventions 
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using established methods and functional 
outcomes. The timing of these interven-
tions in relation to the diagnosis of diabe-
tes should be considered. Given the 
burden of diagnosis, interventions aimed 
at health care professionals providing care 
at the time of diabetes diagnosis should be 
considered. Research into the facilitators 
of and barriers to health care profession-
als' engagement with comorbidity is 
needed. Health services research is re-
quired to find the optimal way of de-
livering interventions. 
Currently researched models of care 
often do not match the reality of primary 
care and so alternative methodologies, 
such as practice-based research net-
works, pragmatic trials, systems science, 
and longer-term observational studies 
that include patient-reported outcomes, 
should be considered. 
Population-based interventions to 
reduce common etiological factors for di-
abetes and depression should be devel-
oped and tested in experimental studies. 
Public Health Considerations. Translating 
basic and clinical research findings into 
improved treatment and outcomes 
remains a substantial challenge. While 
multidisciplinary team care approaches 
have shown efficacy for both diabetes 
and depression, much work remains to 
identify the methodologies and infra-
structure needed to deliver and imple-
ment best practice into routine health 
care in an economically sustainable 
manner. Given the cross-specialty na-
ture of comorbid diabetes and depres-
sion, further research is needed to 
identify how health care professionals 
working across different disciplines can 
provide integrated health services for 
people with comorbidity. Additional 
work to develop technologies to extend 
collaborative care (e.g., telemedicine, 
patient registries, eHealth, mHealth) to 
patients and providers is needed while 
weighing the relative benefits of depres-
sion control in light of multiple health 
outcomes (e.g., glucose, blood pressure, 
lipid, and tobacco control). National and 
local initiatives to develop payment ap-
proaches to support case management 
are needed to insure the successful im-
plementation of large-scale integrated 
care interventions. 
Most of the published economic anal-
yses of the comorbidity of diabetes and 
depression have been undertaken in the 
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U.S.; further research is needed in other 
parts of the world. Collaborative studies 
using cross-culturally applicable assess-
ment methods would be valuable be-
cause they would clarify the impact of 
culture on the presentation, course, and 
outcome of depression and diabetes and 
allow the development of different 
yet effective interventions and models 
of service. Longer-term studies that 
take a broader view of the costs, includ-
ing non-health care-related costs, are 
needed to evaluate cost-effectiveness 
as cost benefits are not usually realized 
immediately. 
TRAINING FOR RESEARCH AND 
CLINICAL CARE 
Training is needed to enhance the work-
force involved in both research and clinical 
care of diabetes and depression. Many re-
searchers and practitioners currently work 
within single disease fields. It is critical 
that training moves research and practice 
to account for the complexity of multiple 
comorbid diseases that are the norm for 
real-world patients. Training should pro-
mote the development of cross-disciplinary 
researchers who can work in teams to 
understand the mechanisms of comor-
bid conditions better and to develop 
effective prevention and treatment ap-
proaches. Researchers with basic science 
and clinical research expertise in neuro-
science, neuroendocrinology, neuroim-
munology, behavioral science, clinical 
psychology, public health, clinical trials, 
and medicine (e.g., psychiatry, inter-
nal medicine, pediatrics) will all be nec-
essary to advance this field. As well as 
working across disciplines, training is 
needed to develop researchers who can 
move across different levels of the trans-
lational continuum from basic to applied 
clinical, behavioral, and population sci-
ence and back again. As in many fields, 
scientific advancement is stunted without 
a cadre of researchers that can span the 
translational chasms between the basic, 
applied, and population sciences. 
Training to expand the workforce 
health care professionals and extenders 
(e.g., community health workers, peer 
supporters) adept in managing comorbid 
depression and diabetes is needed. 
However, given the scope of the needs 
in high-, middle-, and low-income coun-
tries, cost-efficient approaches to ex-
panding the workforce will be critical. 
Mental health providers, diabetes 
behavioral researchers, diabetologists, di-
abetes educators, primary care providers, 
nursing and mid level provider staff, and 
community-based providers are some 
examples of professions where additional 
training in detection, prevention, and 
treatment related to comorbid diabetes 
and depression could be beneficial. 
CONCLUSION 
The association between diabetes and de-
pression or depressive symptoms is a 
major public health problem. A more de-
tailed understanding of the association is 
needed, with greater clarity and precision 
in the terminology used to differentiate 
between depressive symptoms and for-
mal clinical diagnoses of depression. 
These advances in understanding should 
be coupled with the introduction of 
evidence-based interventions into health 
care if we are to resolve the challenge 
of the comorbidity and to improve the 
outcomes for people with comorbid dia-
betes and depression. 
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